[1
]
From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B.,
E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer
Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.)
- both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor
Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill
Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology,
Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York;
Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department
of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.),
and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.)
- both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine,
Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine,
Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division
of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department
of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns
Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.).